Cormorant Asset Management’s Cabaletta Bio CABA Stock Holding History

Cormorant Asset Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.6M	Sell	5,000,000 -500,000	-9%	-$1.64M	0.8%	30
2026 Q1	$14.8M	Buy	5,500,000 +1,100,000	+25%	+$3.05M	0.74%	32
2025 Q4	$9.64M	Sell	4,400,000 -600,000	-12%	-$1.49M	0.45%	30
2025 Q3	$11.7M	Hold	5,000,000	–	–	0.81%	29
2025 Q2	$7.6M	Buy	+5,000,000	New	+$7.8M	0.57%	32
2024 Q2	–	Sell	-1,100,000	Closed	-$18.8M	–	57
2024 Q1	$18.8M	Buy	+1,100,000	New	+$23.6M	0.82%	34
2023 Q4	–	Sell	-2,879,424	Closed	-$43.8M	–	49
2023 Q3	$43.8M	Buy	2,879,424 +657,685	+30%	+$8.99M	2.56%	12
2023 Q2	$28.7M	Buy	2,221,739 +400,000	+22%	+$4.34M	1.61%	16
2023 Q1	$15.1M	Sell	1,821,739 -150,000	-8%	-$1.4M	0.99%	28
2022 Q4	$18.2M	Buy	1,971,739 +817,315	+71%	+$2.98M	1.22%	28
2022 Q3	$750K	Hold	1,154,424	–	–	0.05%	66
2022 Q2	$1.22M	Hold	1,154,424	–	–	0.09%	67
2022 Q1	$2.34M	Hold	1,154,424	–	–	0.18%	62
2021 Q4	$4.38M	Sell	1,154,424 -457,199	-28%	-$4.88M	0.26%	56
2021 Q3	$19.6M	Hold	1,611,623	–	–	0.8%	36
2021 Q2	$13.9M	Sell	1,611,623 -292,801	-15%	-$2.88M	0.47%	50
2021 Q1	$21.1M	Hold	1,904,424	–	–	0.47%	48
2020 Q4	$23.8M	Sell	1,904,424 -162,878	-8%	-$2.11M	0.57%	42
2020 Q3	$22.4M	Sell	2,067,302 -38,542	-2%	-$443K	0.86%	37
2020 Q2	$23.5M	Sell	2,105,844 -2	-0%	-$15	0.9%	36
2020 Q1	$15.4M	Sell	2,105,846 -13,286	-0.6%	-$182K	0.71%	40
2019 Q4	$29.6M	Buy	+2,119,132	New	+$25.1M	1.18%	29

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Cormorant Asset Management's CABA Position: Q2 2026 in Review

Cormorant Asset Management reduced its Cabaletta Bio (CABA) stake by 9.1% in Q2 2026, selling an estimated $1.64M and leaving 5,000,000 shares worth $15.6M. The position accounts for 0.8% of the portfolio, ranked #30.

Cormorant Asset Management first reported a position in CABA in Q4 2019 and has held it in 22 quarters since. The position peaked at $43.8M in Q3 2023. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Cormorant Asset Management held 5,000,000 shares of Cabaletta Bio worth $15.6M as of Q2 2026.
Cormorant Asset Management sold 500,000 Cabaletta Bio shares in Q2 2026, an estimated $1.64M.
Cabaletta Bio made up 0.8% of Cormorant Asset Management's portfolio in Q2 2026, its #30 holding.
Cormorant Asset Management first reported a position in Cabaletta Bio in Q4 2019 and has held it in 22 quarters since.
Cormorant Asset Management's Cabaletta Bio position peaked at $43.8M in Q3 2023.
139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.